Stay updated on Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    ClinicalTrials.gov updated the page’s revision label from v3.5.2 to v3.5.3, indicating a site/version refresh rather than a change to the study record content.
    Difference
    0.1%
    Check dated 2026-04-25T05:27:42.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-18T03:48:24.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.1%
    Check dated 2026-03-20T01:46:14.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Site version updated from v3.4.2 to v3.4.3, with no visible changes to study details or page layout.
    Difference
    0.1%
    Check dated 2026-03-05T18:38:47.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T01:45:29.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Page footer revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:46:54.000Z thumbnail image

Stay in the know with updates to Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.